The present study demonstrated that hepatocyte TMEM16A aggravates hepatic glucose metabolic disorder, steatosis, insulin resistance, and inflammation induced by HFD, thus promoting the development of NAFLD. This evidence concerns the gene ANO1 and metabolic dysfunction-associated steatotic liver disease.